Interval compression may be useful in metastatic Ewing sarcoma

Switching between vincristine/doxorubicin/cyclophosphamide and ifosfamide/etoposide switching every 2 weeks produced similar outcomes for patients with metastatic Ewing sarcoma (ES) as other established regimens suggesting an interval compression (IC) approach could be included with other blocks of therapy, according to a study.

A total of 34 pediatric patients with metastatic ES, of which 26 (76%) had pulmonary metastases and 14 (41%) had extrapulmonary metastases, were included in this study. All patients received local control therapy including surgery alone in 7 patients (21%), radiotherapy only in 18 patients (53%), or surgery and radiotherapy in 9 patients (26%).

The estimated 3-year overall survival (OS) was 62%±9% and event-free survival was 39%±9%. The 3-year OS in patients with pulmonary-only was 88%±8% and in patients with extrapulmonary metastasis it was 27%±13%. Survival was not affected by age group or primary tumor site, however, local control therapy was found to impact survival

(surgery only, 83%±15%; combined surgery and radiation, 30%±18%; radiation only, 15%±10%; P = 0.048).

Reference
Zandaki D, Ismael T, Halalsheh H, et al. Outcomes of Pediatric Patients With Metastatic Ewing Sarcoma Treated With Interval Compression. J Pediatr Hematol Oncol. 2022;doi: 10.1097/MPH.0000000000002478. Epub ahead of print. PMID: 35537074.